N
SRNE

Natixis’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Natixis’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,147
Closed -$60K – 1404
2022
Q3 		$60K Buy
37,147
+22,147
+148% +$50.2K ﹤0.01% 1005
2022
Q2 		$30K Sell
15,000
-42,830
-74% -$74.1K ﹤0.01% 1082
2022
Q1 		$135K Buy
57,830
+42,100
+268% +$131K ﹤0.01% 1118
2021
Q4 		$73K Buy
+15,730
New +$97.7K ﹤0.01% 1194
2021
Q2 		– Sell
-10,700
Closed -$88K – 1175
2021
Q1 		$88K Sell
10,700
-301,100
-97% -$3.18M ﹤0.01% 1043
2020
Q4 		$2.13M Buy
311,800
+263,040
+539% +$2.11M 0.01% 674
2020
Q3 		$544K Buy
+48,760
New +$446K ﹤0.01% 598

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Natixis's SRNE Position: Q4 2022 in Review

Natixis sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 37,147 shares — an estimated $60K sold.

Natixis first reported a position in SRNE in Q3 2020 and held it in 7 quarters. The position peaked at $2.13M in Q4 2020. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

  • Natixis reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Natixis sold 37,147 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $60K.
  • Natixis first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 7 quarters.
  • Natixis's Sorrento Therapeutics, Inc. position peaked at $2.13M in Q4 2020.
  • 221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.